社区

[Medical Technology] On May 7, the National Health Commission introduced the progress of high-quality development in public hospitals. Efforts have been continuously made to construct a new system, leading new trends, enhancing new efficiency, initiating new driving forces, and fostering a new culture. Among them, Jiangsu Province, as a demonstration city for the reform and high-quality development of existing public hospitals, is promoting the optimization and strengthening of national pilot hospitals. Nanjing Drum Tower Hospital has seized the opportunity as a pilot hospital for high-quality development, strengthened technological innovation, and has seen a significant increase in major projects funded by the Ministry of Science and Technology and the National Natural Science Foundation in the past two years.

To promote "Internet + Nursing Services," many provinces across the country have implemented various degrees of "Internet + Nursing Services." Currently, more than 3,000 medical institutions provide over 60 projects in seven categories of medical nursing services, allowing patients to receive corresponding nursing services at home.

Source: National Health Commission of the People's Republic of China, as of May 7, 2024.

Learn more about the Global X China Biotech ETF (2820) $GX中国生科(02820)$ and detailed risk disclosures: https://www.globalxetfs.com.hk/funds/china-biotech-etf/

Learn more about the Global X China MedTech ETF (2841) $GX中国医疗科技(02841)$ and detailed risk disclosures: https://www.globalxetfs.com.hk/funds/china-medtech-etf/

#China #Medtech #Biotech #Thematic #ETF #GlobalXETFsHongKong #GlobalX

-

This material is intended for Hong Kong investors only. It is not a solicitation, offer, or recommendation to buy or sell any security or other financial instrument. Investment involves risks. Past performance information presented is not indicative of future performance. Investing in the funds may expose to risks (if applicable) including general investment risk, equity market risk, sector/market concentration risk, active / passive investment management risk, tracking error risk, trading risk, risk in investing financial derivative instruments, securities lending risk, distributions paid out of capital or effectively out of capital risk. Investors should refer to the Fund's prospectus for details, including the risk factors. Issuer: Mirae Asset Global Investments (Hong Kong) Limited. This material has not been reviewed by the Securities and Futures Commission. Copyright © 2024 Mirae Asset Global Investments. All rights reserved.